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Copyright © 200? JCBN Summary Nω-Carboxymethyl-arginine (CMA), Nω-carboxyethyl-arginine (CEA) and Nδ-(5-
hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) have been identified as L-arginine-
derived advanced glycation end products (AGEs) formed by non-enzymatic reactions between
reducing sugars such as glucose and amino groups in proteins. These AGEs are structurally
analogous to endogenous inhibitors of nitric oxide synthases (NOS) including NG-monomethyl-
L-arginine (L-NMMA) and asymmetric N G,NG-dimethyl-L-arginine (ADMA). Increased
plasma levels of these NOS inhibitors, and thus impaired generation of NO in vivo has been
associated with the pathogenesis of vascular complications such as kidney failure and
atherosclerosis. For these reasons we examined whether L-arginine-derived AGEs inhibit the
activities of three L-arginine metabolizing enzymes including three isoforms of NOS (endo-
thelium, neuronal and inducible NOS), dimethylarginine dimethylaminohydrolase (DDAH)
that catalyzes the hydrolytic degradation of L-NMMA and ADMA to L-citrulline, and arginase
that modulates intracellular L-arginine bioavailability. We found that AGEs inhibited the in
vitro activities of endothelium type NOS weakly (IC50 values of CMA, CEA and MG-H1 were
830, 3870 and 1280 µM, respectively) and were also potential endogenous inhibitors for
arginase (IC50 values of CMA and CML were 1470 and 1060 µM), but were poor inhibitors for
DDAH. These results suggest that the tested L-arginine- and L-lysine-derived AGEs appear
not to impair NO biosynthesis directly.
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Introduction
Advanced glycation end products (AGEs) are a group of
post-translationally modified proteins which are formed
from the reactions between amino residues and reducing
sugars such as glucose. Levels of glycated proteins increase
with aging under normal physiological conditions and alter
the molecular structure and biochemical functions of the
effected proteins. Hyperglycemia accelerates the glycation
and leads to excessive accumulation of AGEs-modified
proteins in vessel walls and has been linked to the patho-
genesis of diabetic complications, particularly the develop-
ment of micro- and macrovascular diseases [1, 2]. Previous
studies have shown that AGEs-modified proteins quench
nitric oxide (NO), an endothelium-derived vasodilator, in
vitro [3, 4] and also decrease the enzymatic activities and
protein expression of endothelium NO synthase (eNOS) inY.-L. Lai et al.
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vascular endothelium cell cultures [5–7]. These results
suggest that AGEs impair NO biosynthesis, playing a critical
role in diabetic endothelial dysfunction.
The reactive dicarbonyl intermediates (glyoxal and methyl-
glyoxal) that are generated from auto-oxidation of glucose
and the glycolysis pathway [8, 9] rapidly modifies the amino
groups of arginine and lysine residues. Some glycated argi-
nine derivatives have been structurally characterized as Nω-
carboxymethylarginine (CMA) [10], Nω-carboxyethylarginine
(CEA) [11] and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-
ornithine (MG-H1) [12] (see structures in Fig. 1). Several
previous studies have shown that the levels of glycated
arginine derivatives are markedly elevated in the plasma of
patients with diabetic complications compared with those in
healthy individuals [13]. In addition, immunohistochemical
studies have demonstrated that CMA accumulates in the
atherosclerotic lesions of human aorta, the CMA levels in
tissue proteins being positively correlated with the patho-
genesis of atherosclerosis [14].
NO, identified as an endothelium-derived relaxing factor
(EDRF), is a critical signaling molecular in vascular func-
tion and homeostasis in mammals [15]. NO is formed during
the oxidation of L-arginine to L-citrulline that is catalyzed
by NO synthases (NOSs, EC 1.14.13.39). Three NOS iso-
forms have been characterized and cloned: neuronal NOS
(nNOS; type I) and inducible NOS (iNOS; type II), endo-
thelial NOS (eNOS; type III) [16]. Constitutive NOS (eNOS
and nNOS) are associated with the regulation of vascular
tone in blood vessels and neurotransmission in the central
and peripheral nervous tissues. In the immune system,
inflammatory cytokines stimulate iNOS expression in
macrophages and other cell types to provide defense against
pathogens.
NG-Monomethyl-L-arginine (L-NMMA) and NG,NG-
dimethyl-L-arginine (asymmetric dimethylarginine; ADMA)
are L-arginine analogues and typical endogenous NOSs
inhibitors (see structures in Fig. 1). It has been demonstrated
that levels of these methylarginines are elevated in plasma
and tissues of patients with various pathological conditions,
including hypertension [17], chronic renal failure [18] and
Fig. 1. Structures of L-arginine-derived AGEs and other compounds used in this study. (a) and (b) endogenous NOS inhibitor, L-
NMMA and ADMA, respectively; (c)–(e) L-arginine-derived AGEs, CMA, CEA and MG-H1; (f) L-arginine; (g) L-lysine-
derived AGEs, CML; (h) an intermediate metabolite in the L-arginine-NO biosynthesis pathway, NOHA; (i) nor-NOHA, a
synthetic analog of NOHA. Dotted circles indicate variable chemical groups of L-arginine derivatives.Effects of AGEs on L-Arginine Metabolizing Enzymes
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diabetes mellitus [19], resulting in a deficiency of endo-
genous biosynthesis of NO due to inhibition of NOSs, espe-
cially eNOS.
Methylarginines are generated by the methylation of
L-arginine residues in proteins mediated with S-
adenosylmethionine: protein arginine methyltransferases
(protein methylases). The methyl groups are symmetrically
or asymmetrically-adducted to the guanidino group of L-
arginine, resulting in formation of L-NMMA and AMDA
(see structures in Fig. 1). Endogenous methylarginines are in
part excreted by the kidney. However the metabolism of L-
NMMA and ADMA, but not NG,NG'-dimethyl-L-arginine
(symmetric dimethylarginine, SDMA), mainly occurs via
hydrolytic degradation to L-citrulline and either monomethyl-
amine or dimethylamine by the enzyme dimethylarginine
dimethylaminohydrolase (DDAH) [20]. Inhibition of DDAH
activity increases intracellular concentrations of ADMA
and reduces endogenous NO generation [21]. It has been
reported that a glucose-induced impairment of DDAH
causes the accumulation of ADMA and this may contribute
to endothelial vasodilator dysfunction in patients with
diabetes [22].
The NO generation depends on the bioavailability of
NOSs substrate L-arginine which is shared by arginase,
the enzyme metabolizing L-arginine to form urea and L-
ornithine via the urea cycle [23]. Arginase is responsible
for regulating NO generation by modulating intracellular
L-arginine bioavailability. It has been reported that increases
in arginase activity diminish plasma levels of L-arginine in
human diabetes patients and experimental diabetic animals
[24, 25].
The present study has focused on several endogenous
AGEs-derived compounds including L-arginine derivatives
(CMA, CEA and MG-H1) and an L-lysine derivative
(carboxymethyl-lysine, CML). Because these compounds
are structurally analogous to endogenous NOSs inhibitors
L-NMMA and ADMA, they may be implicated in the
pathological mechanism of chronic vasculopathy through
competitive inhibition of NOSs activities, especially eNOS.
These L-arginine derivatives may impair NO generation
by antagonizing L-arginine binding sites of three NOS
isoforms. In addition to NOS we have also examined the
effects of these compounds on the enzymatic activities of




L-Arginine, ADMA, NG-hydroxy-L-arginine (NOHA),
nicotinamide adenine dinucleotide phosphate reduced form
(NADPH), flavin adenine dinucleotide (FAD), flavin mono-
nucleotide (FMN), (6R)-5,6,7,8-tetrahydrobiopterin (BH4),
recombinant eNOS (from bovine), iNOS (from mouse
macrophage), Dowex® AG50W-X8 cation-exchange resin
(mesh size, 100–200) were all purchased from Sigma
Chemicals (St. Louis, MO). Ultima Gold XR scintillation
liquid was from PerkinElmer (Shelton, CA). Recombinant
nNOS (from rat) and NG-hydroxy-nor-arginine (nor-NOHA)
were obtained from Cayman Chemicals. Arginase (from
bovine liver) was from Alexis Biochemicals (Lausen,
Switzerland). L-NMMA was from Calbiochem, Darmstadt,
Germany. All other chemicals were obtained from Wako
Pure Chemical Industries, Osaka, Japan.
Synthesis of L-arginine-derived AGEs
CMA, CEA and MG-H1 were synthesized and purified
according to the methods described previously [26]. Their
structures were confirmed by nuclear magnetic resonance
and electrospray ion mass spectrometry. Purities of these L-
arginine derivatives were over 98%, which was verified by
high performance liquid chromatography equipped with a
fluorescence detector after derivatization with the fluores-
cent reagent 4-fluoro-7-nitro-2,1,3,-benzoxadiazole [27].
Assay for NOSs activities
The NOS activities were determined by monitoring the
conversion of L-[14C(U)]-arginine (Moravek, Brea, CA) to
L-[14C(U)]-citrulline as previously described [28]. Recombi-
nant enzymes of three isoforms of NOS (specific activity:
eNOS 0.03, nNOS 2.9, iNOS 0.62 units/mg protein) (10 μl)
were added to a reaction mixture (final volume of 100 μl)
consisting of 50 mM HEPES buffer (pH 7.4), 1 mM
NADPH, 4 μM FAD, 4 μM FMN, 10 μM BH4, 1 mg/L
calmodulin, 2.5 mM CaCl2, 50 µM L-arginine and 0.5 µCi/ml
of L-[14C(U)]-arginine (specific activity: 8.14–11.1 GBq/
mmol). After incubation for 30 min at 37°C, the reactions
were terminated by addition of 0.5 ml of 20 mM HEPES
(pH 5.5) containing 2 mM EDTA and 2 mM EGTA. Samples
were passed through a 1 ml column of Dowex AG50W-X8
(Na+-form) to remove unconverted L-[14C(U)]-arginine. L-
[14C(U)]-Citrulline was eluted twice with 1 ml of distilled
water, and the eluted fractions mixed with 10 ml of cocktail
(Ultima Gold XR) were quantified using a liquid scintilla-
tion counter. A reaction mixture containing L-[14C(U)]-
arginine without the enzyme was incubated as a control to
determine background counts. The effects of arginine deriva-
tives on the NOSs activities were examined in the presence
and absence of the test compounds at various concentrations.
Assay for arginase activity
Assays for arginase activity were performed by monitoring
the conversion of L-[guanidine-14C]-arginine (Moravek,
Brea, CA) to [14C]-urea as previously described [28].
Recombinant arginase (0.5 μg of protein, specific activity:
0.094 units/mg protein) (10 μl) was added to a mixture (finalY.-L. Lai et al.
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volume of 100 μl) containing 10 mM Tris-HCl buffer,
pH 9.6, 1 mM MnCl2, and 0.16 µCi/ml of L-[guanidine-14C]-
arginine (specific activity: 1.85–2.22 GBq/mmol). After
incubation for 1 h at 37°C, the reactions were terminated by
addition of 0.4 ml of stop buffer containing 250 mM sodium
acetate and 100 mM urea, pH 4.5. Samples were then passed
through a 1 ml column of Dowex AG50W-8X (Na+-form)
to remove unmetabolized L-[guanidine-14C]-arginine. [14C]-
Urea was eluted twice with 1 ml of distilled water, and
the eluted fractions mixed with 10 ml of cocktail (Ultima
Gold XR) were quantified using a liquid scintillation counter.
A reaction mixture containing L-[guanidine-14C]-arginine in
the absence of enzyme was incubated as a control to deter-
mine background counts. The inhibitory effects of arginase
were examined in the presence and absence of the test
compounds at various concentrations.
Assay for dimethylarginine dimethylaminohydrolase (DDAH)
activity
The DDAH activity was determined by monitoring the
conversion of L-[4,5-3H]-NMMA (American Radiolabeled
Chemicals, Inc., St. Louis, MO) to L-[3H]-citrulline as pre-
viously described [28, 29]. Rat kidney tissues (0.5 g) were
homogenized in 1 ml of ice-cold 0.1 M sodium phosphate
buffer (SPB, pH 6.5), and then centrifuged at 10,000 rpm for
5 min at 4°C. The supernatants were analyzed for protein
content using a BCA protein reagent kit with bovine serum
albumin as the standard. The supernatants were diluted with
SPB to 1 mg protein in 50 μl, and then were added to a reac-
tion mixture (a final volume of 100 μl) containing 0.1 M
SPB (pH 6.5) and 0.1 μCi/ml of L-[3H]-NMMA (specific
activity: 1.48–2.96 TBq/mmol). After incubation for 1 h at
37°C, the reactions were terminated by keeping the tubes on
ice for 5 min. Samples were then passed through a 1 ml
column of Dowex AG50W-8X (Na+-form) to remove un-
metabolized L-[3H]-NMMA. L-[3H]-Citrulline was eluted
twice with 1 ml of distilled water, and the eluted fractions
mixed with 10 ml of cocktail (Ultima Gold XR) were
quantified using a liquid scintillation counter. A reaction
mixture containing L-[3H]-NMMA in the absence of enzyme
was added to the Dowex column to determine background
counts. The effects of arginine derivatives on the enzyme
activities in the presence and absence of the test compounds
at various concentrations were examined.
Statistical analysis
All experiments were repeated 3~8 times. Representative
results are shown as means ± standard deviations (SD). For
statistical comparison between two groups, an unpaired t test
was used.
Fig. 2. Inhibitory effects of various AGEs and other compounds
on the enzymatic activities of three isoforms of NOSs,
(A) eNOS, (B) iNOS and (C) nNOS. A reaction mixture
containing a recombinant NOS, necessary cofactors,
50 μM L-arginine (including L-[14C(U)]-arginine) and a
test compound at indicated concentration was incubated
for 30 min at 37°C. Results are shown as the means ±
S.D normalized to a value of 100% for control (the
absence of compounds) (n = 4–8). Significantly different
when compared with the control, *p<0.05, **p<0.01. L-
NMMA (closed triangle), ADMA (open triangle), CMA
(closed circle), CEA (open circle), MG-H1 (closed
square) and CML (open square).Effects of AGEs on L-Arginine Metabolizing Enzymes
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Results
Effects of L-arginine-derived AGEs on activities of three
NOS isoforms
The effects of four AGEs compounds (CMA, CEA, MG-
H1 and CML) on the activities of three NOS isoforms were
examined at final concentrations of 5, 50, 500, 2500, and
5000 µM. The conversion of L-[14C(U)]-arginine to [14C(U)]-
citrulline by NOS isoforms was decreased in a concentration-
dependent manner when the enzymatic reaction was carried
out in the presence of these AGEs. In particular, the eNOS
activity was efficiently inhibited by CMA (IC50 value of
830 ± 36 μM) and MG-H1 (IC50 value of 1280 ± 75 μM),
but not by CEA (IC50 value of 3870 ± 680 μM) and CML, a
glycated L-lysine derivative (IC50 value >5000 µM) (Fig. 2A,
Table 1). On the other hand, L-NMMA and ADMA, well
known inhibitors for NOSs, inhibited the activities of eNOS
strongly with IC50 values being 5 ± 1 and 16 ± 9 μM, respec-
tively. Similar to eNOS, the iNOS activity was also inhibited
by CMA (1160 ± 40 μM), MG-H1 (2970 ± 560 μM), but
not by CEA and CML (both IC50 values of >5000 μM)
whereas L-NMMA and ADMA inhibited iNOS activities
with IC50 values of 10 ± 3 and 24 ± 1 μM, respectively
(Fig. 2B, Table 1). The nNOS activity was moderately
inhibited by CML (1930 ± 300 μM), MG-H1 (4170 ± 380
μM), and very little by CMA and CEA (with IC50 values
of >5000 μM (Fig. 2C, Table 1). L-NMMA and ADMA
inhibited the activities of nNOS with IC50 values being 8 ± 2
and 23 ± 0 μM, respectively.
Effects of L-arginine-derived AGEs on activities of arginase
and DDAH
The metabolism of L-[guanidine-14C]-arginine to [14C]-
urea mediated by arginase was diminished by the presence
of AGEs compounds. In particular, CML suppressed the
formation of [14C]-urea in a dose-dependent manner with an
IC50 value of 1060 ± 60 μM, whereas CMA inhibited the
arginase activity with an IC50 value of 1470 ± 120 μM. CEA
and MG-H1 showed very little inhibition at the concentra-
tions tested with IC50s >5000 µM (Fig. 3A, Table 2). NOHA,
an intermediate metabolite in the L-arginine-NO biosynthesis
pathway, and nor-NOHA, a synthetic analog of NOHA, are
known inhibitors for arginase [30] and efficiently inhibited
the activity of arginase in a dose-dependent manner, with the
IC50 values being 230 ± 26 and 340 ± 12 μM, respectively
(Fig. 3A, Table 2).
The enzymatic activity of DDAH was assayed by counting
the amounts of L-[3H]-citrulline catalytically formed from
L-[3H]-NMMA by a homogenate of rat kidney tissue [28,
29]. AGEs (CMA, CEA, MG-H1 and CML) were found to
exhibit weak inhibitory effects on DDAH activity with IC50
values being >5000 μM for each compound (Fig. 3B,
Table 2). We have also examined the inhibitory effect of
nor-NOHA, a structurally-analogous compound to a potent
DDAH inhibitor S-2-amino-4(5-methylguanidino) butamoic
acid (4124W) [21]. nor-NOHA inhibited DDAH activity
with an IC50 value of 1770 ± 250 μM.
Discussion
We have examined our hypothesis that L-arginine-derived
AGEs, CMA, CEA and MG-H1 may inhibit L-arginine
metabolism such as the biosyntheses of NO and urea, and
contribute to the pathogenesis of vascular complications
such as kidney failure and atherosclerosis in diabetes
patients. L-Arginine-derived AGEs are structurally analogous
to the endogenous NOS inhibitor methylarginine and their
levels have been reported to be markedly elevated in the
plasma of patients with diabetes compared with those in
healthy individuals [13,  31]. For these reasons we have
synthesized CMA, CEA and MG-H1 and examined their
effects on the enzymatic activities of three isoforms of NOS
as well as DDAH and arginase that are enzymes which
indirectly regulate NO bioavailability.
We found that glycated L-arginine derivatives (CMA,
CEA and MG-H1) inhibited all of three NOS isoforms
Table 1. The IC50 values of various arginine derivatives for inhibition of three isoforms of NOS.
The effects of various L-arginine derivatives on the activities of three isoforms of NOSs were mea-
sured as described in Materials and Methods. The values correspond to concentrations necessary for




L-NMMA 5 ± 11 0 ± 38 ± 2
ADMA 16 ± 92 4 ± 12 3 ± 0
CMA 830 ± 36 1160 ± 40 >5000
CEA 3870 ± 680 >5000 >5000
MG-H1 1280 ± 75 2970 ± 560 4170 ± 380
CML >5000 >5000 1930 ± 300Y.-L. Lai et al.
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(eNOS, nNOS, and iNOS) as well as arginase, whereas
they did not show inhibitory effects on DDAH activity. The
glycated L-lysine derivative (CML) inhibited arginase, but
not NOSs and DDAH. However, the IC50 values of these L-
arginine derivatives were 3 to 1000-fold higher than those
of the synthetic endogenous NOS inhibitors such as ADMA
and NOHA.
Reactive α-oxoaldehydes of glyoxal and methylglyoxal
(the major AGEs precursors) react with L-arginine and L-
lysine residues in protein to form AGEs such as CMA, CEA,
MG-H1 and CML. AGEs-modified proteins accumulate in
tissues age-dependently and their accumulation is increased
under some pathophysiological conditions. Thornalley et al.
[31] determined the concentrations of 12 AGEs including
MG-H1 and CML by liquid chromatography-mass spectro-
metry (LC-MS) after enzymatic hydrolysis and found signifi-
cantly increased levels of AGEs residues in plasma proteins
(up to 7-fold) in patients with renal failure compared to those
in normal healthy subjects. Similarly the concentrations of
CMA residues in serum protein analyzed by LC-MS were
~1.5-fold higher in patients with diabetes without renal
failure than in normal subjects [13]. In addition, the levels of
free MG-H1 and CML were reported to be 0.11 μM and
0.023 μM in plasma of normal individuals, whereas their
levels rose to approximately 5.5 μM and 0.2 μM, respec-
tively, in patients with end-stage renal disease [31]. Under
our  in vitro assay conditions, these AGEs compounds
inhibited NOS activities with IC50 values being >830 μM. It
is therefore unlikely that glycated L-arginine and L-lysine
derivatives such as CMA, CEA, MG-H1 and CML competi-
tively inhibit the enzymatic activities of the three isoforms
of NOS.
Many studies have demonstrated that elevated plasma
levels of ADMA might contribute at least in part to the
molecular mechanisms of vasculopathy by impairment of
NO-dependent vasodilation under various pathophysiological
states [17–19]. The plasma concentrations of ADMA found
in healthy populations are 0.5 ~ 1.2 μM, whereas they in-
crease up to 10-fold in patients with end-stage renal disease
and more moderately (2–3 fold) in many other disease states
including chronic heart failure and hypercholesterolemia
[32, 33].
Free methylarginines, derived from the degradation of
methylated proteins and more than 90% of L-NMMA and
ADMA, but not symmetric dimethylarginine (SDMA), are
Fig. 3. Inhibitory effects of various AGEs and other compounds
on the enzymatic activities of arginase and DDAH. (A)
The enzymatic activities of arginase were measured by
incubation of a reaction mixture containing recombinant
arginase, 1 mM MnCl2, substrate of L-[guanidine-14C]-
arginine and test compounds at the indicated concentra-
tions. (B) The enzymatic activities of DDAH were mea-
sured by incubation of a reaction mixture containing rat
kidney extracts, L-[3H]-NMMA and test compounds at
the indicated concentrations in SPB (pH 6.5). Results are
shown as the means ± S.D normalized to a value of
100% for control (the absence of compounds) (n = 4–8).
Significantly different when compared with the control,
*p<0.05, **p<0.01. nor-NOHA (closed diamond), NOHA
(open diamond), CMA (closed circle), CEA (open circle),
MG-H1 (cloaed square) and CML (open square).
Table 2. The IC50 values of various arginine derivatives for inhi-
bition of arginase and DDAH.
The effects of various L-arginine derivatives on the activities of
arginase and DDAH were measured as described in Materials and
Methods. The values correspond to concentrations necessary for
50% inhibition of enzyme activities. Results are means ± SD




Nor-NOHA 230 ± 26 1770 ± 250
NOHA 340 ± 12 ND
CMA 1470 ± 120 >5000
CEA >5000 >5000
MG-H1 >5000 >5000
CML 1060 ± 60 >5000Effects of AGEs on L-Arginine Metabolizing Enzymes
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mainly metabolized by the enzyme DDAH, which catalyzes
the degradation of L-NMMA and ADMA to form L-
citrulline and monomethylamine or dimethylamine, respec-
tively. DDAH expression is found in many tissues (endo-
thelial cells, brain etc.), but the liver and kidney are the pri-
mary organs responsible for the metabolism of L-NMMA
and ADMA [34]. The concentrations of endogenous NOS
inhibitors modulated by DDAH are associated with L-
arginine/NO-dependent vasodilation. Furthermore recent
studies suggest that ADMA accumulation caused by an
impairment of DDAH due to down-regulation of protein
expression and its decreased activity contributes to abnormal
endothelium-dependent vasodilation in diabetes mellitus
[22, 35]. For these reasons, we have investigated the effects
of AGEs (CMA, CEA, MG-H1 and CML) on the enzymatic
activities of DDAH. The DDAH activity was slightly
inhibited by the test compounds (CMA, MG-H1 and CML)
with an IC50 value being >5000 μM for each compound
(Fig. 3B, Table 2). Even in the presence of the highest
concentrations (5000 μM) of these compounds, the DDAH
activity was inhibited only by approximately 60%. Because
the DDAH inhibitor 4124W [21] could not be obtained
commercially, we examined the effect of nor-NOHA, a
structural analogue to 4124W, on the DDAH activity. We
found that nor-NOHA showed a dose-dependent inhibition
of the conversion of L-[3H]-NMMA to L-[3H]-citrulline with
an IC50 value of 1770 μM. Compared with nor-NOHA,
AGEs exhibited weaker inhibitory effects on the DDAH
activity.
The generation of vasodilator (NO) depends also on the
bioavailability of the NOS substrate, L-arginine, which is
shared by an enzyme arginase forming urea and L-ornithine
via the urea cycle [36]. It has been reported that an increased
activity of arginase causes diminished levels of plasma
L-arginine in human diabetes patients and experimental
diabetic animals [24, 25]. For these reasons, we examined
the effects of AGEs compounds on the arginase activity.
CML and CMA (IC50 values of 1060 and 1470 μM, respec-
tively), but not CEA and MG-H1 (IC50 values >5000 μM),
were found to be moderate inhibitors of arginase, although
the inhibitory efficiencies were approximately 3-fold weaker
than a well known arginase inhibitor, NOHA (IC50 value
340 μM), that is an intermediate of the L-arginine/NO
pathway.
In conclusion, the present study demonstrated that glycated
L-arginine derivatives (CMA, CEA and MG-H1) and an L-
lysine derivative (CML) are potential endogenous inhibitors
for three NOS isoforms (eNOS, nNOS, and iNOS) and
arginase, but are very poor inhibitors for DDAH. The IC50
values were much greater than the well-known endogenous
NOSs and arginase inhibitors such as ADMA and NOHA.
Further studies are needed to determine whether AGEs
(CMA, CEA, MG-H1 and CML) inhibit other arginine
metabolizing enzymes such as argininosuccinate synthase
and argininosuccinate lyase and also affect L-arginine
transport into cells, which is also known to play a role in
the regulation of NO production by cells.
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